Infliximab treatment for steroid-refractory acute graft-versus-host disease.

  title={Infliximab treatment for steroid-refractory acute graft-versus-host disease.},
  author={Francesca Patriarca and Alessandra Sperotto and Daniela Damiani and Giuseppe Morreale and Francesca Bonifazi and Attilio Olivieri and Fabio Ciceri and Giuseppe Milone and Simone Cesaro and G. Bandini and Giorgio Dini and P. Poggi – Corradini and Renato Fanin},
  volume={89 11},
BACKGROUND AND OBJECTIVES Tumor necrosis factor a is one of the principal cytokines involved in the pathogenesis of acute graft-versus-host-disease (GVHD). Infliximab is an antibody to this cytokine. DESIGN AND METHODS We performed a retrospective analysis to evaluate the activity of infliximab in 32 patients with severe steroid-refractory acute GVHD. The patients received a median of 3 weekly courses of infliximab. The main organs involved in the patients were skin (n=2) liver (n=1), bowel… CONTINUE READING